Anavex receives FDA clearance for blarcamesine trial in Fragile X syndrome
AVXL•Anavex Life Sciences received FDA clearance to begin a Phase 2a trial of blarcamesine for Fragile X syndrome. The trial will assess safety, tolerability and pharmacokinetics in approximately 60 adult males.
1. Trial plans
Anavex Life Sciences received FDA clearance to begin a Phase 2a trial of blarcamesine for Fragile X syndrome. The planned trial will assess safety, tolerability and pharmacokinetics in approximately 60 adult males.
